Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Policy Development (PD) Working Group

Policy Development (PD) Working Group

BACK

Policy Development (PD) Working Group

The European Commission has entrusted the Avicenna Alliance with a pivotal mission: supporting the implementation of the Avicenna Roadmap within European policy.

Through its Policy Development Working Group, the Avicenna Alliance is helping shape a future-ready regulatory landscape that fully embraces the potential of in silico technologies. As many existing EU policies and regulations were developed before the emergence of these innovative approaches, there is a clear need to modernize the framework governing healthcare innovation.

By advancing the validation and regulatory acceptance of modelling and simulation, the Avicenna Alliance is paving the way for greater investment, accelerated innovation, and the wider adoption of in silico technologies across healthcare and research.

The Policy Development Working Group Mission is to work towards:

  • A forward-looking policy framework to facilitate the large scale deployment of in silico technology and their acceptance by health authorities.

  • To significantly reducing time and cost for health care technologies approval and reimbursement and fostering medical innovation, including for those conditions with pressing unmet medical needs such as rare diseases and pediatric applications.

The key goals of this group are:

  • Inform European and US authorities about the benefits brought by in silico medicine;
  • Advocate for the inclusion of CM&S (Computer Modelling and Simulation) in legislation, policy guidelines and research funds;
  • Collaborate with health care stakeholders on in silico guidance and CM&S benefits dissemination, ensuring that in silico clinical trials become a pillar of drug and medical device development programs, when appropriate.

Priorities 2025 - 2027 and beyond:

2025:

  • Establish collaboration with EC stakeholders;
  • Define pathway to submit digital evidence to support CE marking;
  • Define GSP in collaboration with FDA, EMA, MDIC and InSilicoWorld;
  • Promote in silico medicine for Pharmaceutical application;
  • Educate stakedholders via NB TF, Pharma Strategy and PPI TF.

2026:

  • Identify policies mentioning payers to promote in silico medicine
  • Foster collaboration with European Commission
  • Promotion of GSP vis-à-vis Worldwide Policy makers (with Int. WG);

2027 and beyond:

  • Sustain in silico advocacy for Medcial Devices and Pharmaceuticals

CLICK HERE FOR POLICY DEVELOPMENT WG INTRO
Martha De Cunha Maluf-Burgman, WG Leader


Martha De Cunha Maluf-Burgman

Martha De Cunha Maluf-Burgman

Policy Development Working Group Leader

Director Regulatory Affairs, Edwards Lifesciences

SEND E-MAIL
READ BIO

NEWS

News ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

On 20 October, Avicenna Alliance was represented by many members and partners, including our President and Secretary General, Thierry Marchal, at the annual VHT Net initiative meeting, organised by the VPH - The Society for In Silico Medicine at the European Commission.

News SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

The Avicenna Alliance is pleased to support initiatives that bring stakeholders together to advance the use of artificial intelligence, synthetic data, and computational modelling and simulation in healthcare.

News Avicenna Days (AAD) 2027

Avicenna Days (AAD) 2027

Three days. One journey. From research to real-world impact.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2026 Avicenna Alliance | powered by We Berry